Percocet 7.5/325

Quick links

Choose a section

Quick links to important sections

Advertisements

Percocet 7.5/325

Advertisements
Advertisements

Treatment option: Pain

Advertisements

Overview of Percocet 7.5/325

Property Description
Active Ingredients Oxycodone Hydrochloride, Acetaminophen
Form Fixed-Dose Combination Tablet (Oral)
Pharmacological Class Opioid and Non-Opioid Analgesic Combination
General Purpose Analgesia for moderate to severe pain
Origin Semisynthetic (Oxycodone) and Synthetic (Acetaminophen)

What is Percocet 7.5/325: A Definition and Classification

Percocet 7.5/325 is a prescription-only medication provided as an immediate-release tablet, classified as a narcotic analgesic combination. This fixed-dose combination (FDC) is structurally distinct from single-agent formulations and is utilized for the management of pain.

The medicine's identity is established by the presence of a semisynthetic opioid analgesic, Oxycodone Hydrochloride, alongside the non-opioid analgesic and antipyretic, Acetaminophen (or Paracetamol). This combined formulation is clinically recognized for its effectiveness in the management of pain that requires the potency of an opioid component.


Composition and Dual-Action Pharmacological Group

The specific designation 7.5/325 is critical, representing the precise quantity of active ingredients in each tablet: 7.5 milligrams (mg) of Oxycodone Hydrochloride and 325 milligrams (mg) of Acetaminophen. This dual composition confers two distinct modes of action to the medicine.

The formulation functions as an opioid agonist and an antipyretic, ensuring the medicine targets pain through complementary routes simultaneously. Pharmacological studies support that combining an opioid with Acetaminophen yields a therapeutic advantage over using the opioid alone. This strategic combination is its primary differentiating factor within the analgesic market.


General Therapeutic Purpose and Function

The general therapeutic purpose of this FDC tablet is the analgesia of moderate to severe pain, which typically requires more than non-opioid options can provide. The medicine works by leveraging the synergistic effects of its two components: the opioid acts centrally to block pain signals, and the non-opioid modifies pain perception while contributing to temperature reduction.

This integrated function offers robust pain relief suitable for various situations, such as post-operative discomfort or injury-related pain. The auxiliary benefit of fever reduction where pain is accompanied by elevated body temperature further underscores the utility of the dual-compound approach.

Regulatory References

  1. DailyMed - OXYCODONE AND ACETAMINOPHEN tablet (NIH)
Advertisements

What side effects are possible with Percocet 7.5/325?

Possible Side Effects and Safety Information

The officially documented safety profile for this combination medicine is defined by risks associated with both the opioid (Oxycodone) and non-opioid (Acetaminophen) components, as specified in government regulatory documents.

Adverse reactions are classified by frequency and system-organ class.

Classification Examples of Reactions
Common Reactions Nausea, vomiting, constipation, somnolence (drowsiness), dizziness, and headache.
Serious Reactions Respiratory depression, acute liver failure, circulatory depression, and shock.

Serious adverse reactions are highlighted in official labeling, particularly the risk of Respiratory Depression associated with the opioid component and the risk of Acute Liver Failure linked to the Acetaminophen component. The label includes mandatory safety warnings concerning the risks of Misuse, Abuse, and Addiction inherent to opioid analgesics.

Specific safety considerations are mandated for certain patient populations. Older adults may face a greater risk of adverse effects, including respiratory compromise. Patients with pre-existing hepatic or renal impairment require particular attention due to the metabolism and excretion of the drug’s components. Prolonged use during pregnancy is officially associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

Furthermore, regulatory documents note that Physical Dependence and Tolerance are recognized outcomes that may develop with prolonged use. The label also contains explicit restrictions, such as avoiding co-administration with other Acetaminophen-containing products to prevent exceeding the recommended daily limit and mitigating the risk of hepatotoxicity.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this fixed-dose combination, containing Oxycodone (opioid) and Acetaminophen (non-opioid), is a medical emergency that is potentially life-threatening and requires immediate medical attention.

Overdose manifests as distinct toxicities from both components.


Documented Overdose Manifestations

The opioid component may cause respiratory depression (shallow or slow breathing), extreme somnolence that can progress to coma, miosis (pinpoint pupils), hypotension (low blood pressure), and bradycardia (slow heart rate). The acetaminophen component initially presents with nausea, vomiting, diaphoresis (sweating), and general malaise, leading to the severe risk of fatal hepatic necrosis (liver damage) in a time-delayed manner.


Regulatory Actions and Outcomes

Regulators emphasize that immediate medical intervention is required. Severe outcomes include respiratory arrest, circulatory collapse, and death. The required procedural steps include the administration of specific antidotes: Naloxone for opioid toxicity reversal and N-acetylcysteine (NAC) for preventing or lessening acetaminophen-induced liver injury. Hospital monitoring is required after intervention, and observation is necessary for the recurrence of opioid depression and the development of delayed hepatotoxicity. Patients with pre-existing hepatic impairment are at an increased risk of severe hepatotoxicity.


Action Mandate: Seek immediate emergency medical attention for any suspected overdose or signs of toxicity.

Advertisements

Therapeutic Uses of Percocet 7.5/325

What Percocet 7.5/325 Treats: Main Uses and Benefits

This medication is commonly used to provide symptomatic relief for pain that is considered moderate to severe, where pain creates noticeable physiological strain and may be suboptimally responsive to standard, non-opioid pain relievers. The medication is considered relevant in clinical settings, aligning with official therapeutic guidelines, and is applicable within contexts marked by increased discomfort or tension. It is used across conditions presenting with acute episodes and for managing intense manifestations, such as discomfort associated with acute physical trauma, medical procedures, and sudden, intense breakthrough pain.

The core therapeutic benefit contributes to easing the overall symptom load by supporting pain relief, which helps maintain a sense of stability when symptoms are more noticeable and contributes to functional stability. The combination formula is relevant for managing symptom clusters, which often include symptoms related to physical discomfort and systemic imbalance. This provides supportive relief that assists with maintaining functional stability and supports general well-being during symptomatic phases.

“It is relevant in situations where symptoms escalate temporarily and short-term symptomatic assistance is needed.”


Quick Fact: Relief for Physical Discomfort and Systemic Imbalance

The medication is applied in addressing conditions characterized by periods of heightened symptoms involving intense physical discomfort, which may be linked to systemic imbalance.

Advertisements

Eligibility and Restrictions for Use

Percocet 7.5/325 eligibility is strictly defined by official regulatory documentation that establishes absolute prohibitions and mandates specific cautions based on a patient’s health status.

Populations Excluded from Use (Contraindicated)

The medicine must not be used by individuals with a known hypersensitivity to oxycodone, acetaminophen, or any component of the product. Absolute exclusion criteria also include patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, or known or suspected gastrointestinal obstruction, including paralytic ileus.

Populations with Established Restrictions

Conditional use is required for several groups:

  • Age Groups: Safety and effectiveness have not been established in pediatric patients. Older adults are considered a special risk group, requiring caution due to increased sensitivity to respiratory depression.
  • Organ Function: Caution is required for patients with severe impairment of hepatic function or severe impairment of renal function.
  • Clinical Status: Restrictions apply to those with head injury or increased intracranial pressure, pre-existing respiratory conditions like COPD, or specific endocrine disorders such as hypothyroidism or Addison's disease. Conditional use is also required for patients with a history of substance abuse.
  • Reproductive Status: The medicine is generally not recommended during pregnancy due to the documented risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Use in lactating women requires caution as it is unknown if the components are excreted into human milk.
Advertisements

What should I know about interactions with other medicines?

Percocet 7.5/325 interactions are formally classified based on how other substances modify the product's activity, structured around pharmacokinetic and pharmacodynamic outcomes documented in regulatory sources.

Pharmacodynamic Interactions (Additive Effects)

The most significant interaction is with Central Nervous System (CNS) Depressants, a category that includes benzodiazepines, other opioid analgesics, and general anesthetics. Co-administration with these products results in an officially documented additive CNS depression, which increases the labeled risk of profound sedation and severe respiratory depression. Combining the medication with Serotonergic Drugs is also noted in regulatory documentation to carry a formal risk of developing Serotonin Syndrome. Interactions with Anticholinergics are documented due to the potential for producing paralytic ileus.

Pharmacokinetic Interactions (Exposure Modification)

Interactions affecting the metabolism of the oxycodone component are formally described. CYP3A4 Inhibitors cause a documented pharmacokinetic interaction that increases the plasma concentrations of oxycodone. The subsequent discontinuation of a CYP3A4 Inducer may similarly result in increased oxycodone exposure.

Substance and Population Notes

Alcohol (Ethanol) is explicitly included as a CNS depressant with additive effects, increasing the labeled risk of sedation and respiratory failure. Interactions are also noted with substances such as Grapefruit Juice and the herbal product St. John's wort. Official documentation also highlights that the risk for severe respiratory depression when combined with other depressants is particularly significant for elderly or debilitated patients.

Advertisements

Mechanism of Action

Percocet 7.5/325 contains oxycodone and acetaminophen. The pharmacodynamic mechanism is driven by the actions of these two components.

Oxycodone acts as a mu-opioid receptor ( MOR) agonist within the central nervous system ( CNS) and peripheral tissues.

Binding of oxycodone to the MOR, a G-protein coupled receptor ( GPCR), initiates a conformational change. This leads to the dissociation of the heterotrimeric G-protein, where the Galpha i/o subunit inhibits adenylyl cyclase activity, reducing the intracellular concentration of cyclic adenosine monophosphate ( cAMP). The Gbetagamma subunit opens G-protein-coupled inwardly-rectifying K^+ channels ( GIRK), causing potassium efflux and hyperpolarization of the neuronal membrane. Additionally, the Gbetagamma subunit inhibits voltage-gated Ca^2+ channels, decreasing calcium influx. These intracellular consequences collectively diminish neuronal excitability and neurotransmitter release, resulting in modulated nociceptive signal transmission at the systemic level.

Acetaminophen exhibits an distinct mechanism, primarily through the inhibition of CNS cyclooxygenase ( COX) enzymes, particularly COX-2, which reduces the synthesis of prostaglandins. Acetaminophen may also interact with the descending serotonergic pathways or the cannabinoid system to contribute to its overall systemic physiological modulation.

Advertisements

Dosage and Administration Information

How to Use Percocet 7.5/325: Official Administration Guidelines

The administration of Percocet 7.5/325, a fixed-dose combination (FDC) tablet of Oxycodone Hydrochloride and Acetaminophen, is defined by strict regulatory guidelines. This medicine is exclusively intended for short-term management and is governed by an as-needed (PRN) dosing pattern for use only when alternative, non-opioid treatments are inadequate.


Administration Scope

Instruction Detail
Route of administration Oral administration only.
Dosing schedule The standard adult unit dose is one (1) tablet (7.5 mg/325 mg), taken as needed for pain.
Timing in relation to meals May be taken with or without food.
Special procedural conditions The tablet must be swallowed whole. The use is defined as short-term, intended for discontinuation when the need for opioid analgesia is resolved.

Dosing Limits and Constraints

The official dosing schedule includes strict limits on the total quantity administered. A minimum interval of six (6) hours must be maintained between doses. The total amount administered must not exceed a maximum of eight (8) tablets within any 24-hour period. For patients with severe hepatic or renal impairment, the total daily dose requires careful individualization to account for the toxicity constraints of the Acetaminophen component.


Procedural Summary

The required sequence for use involves ingesting the unit dose orally when needed, maintaining the specified 6-hour interval, and strictly adhering to the mandated daily maximum of eight tablets. This structure ensures the medication is used according to its officially approved, time-restricted, and dose-controlled protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Percocet 7.5/325

The research base for this combination tablet (Oxycodone/Acetaminophen) includes findings from randomized controlled trials (RCTs), systematic reviews, and various observational studies. This overview describes the research structure and the types of evidence regulators rely on, focusing only on the study designs and observed patterns, without providing clinical guidance or statements of effectiveness.

Evidence for Management of Moderate to Severe Acute Pain

This section summarizes the structure of the most robust evidence base, focusing on the randomized controlled trials (RCTs) that examined the medication for short-term pain relief, such as following surgical or dental procedures. Research exploring the outcomes related to acute pain was conducted, and is relevant in trials assessing short-term or episodic symptom patterns. These studies focused on outcomes describing episodic or acute changes, and commonly examined pain intensity scoring and monitoring the time elapsed until trial participants requested additional pain relief.

Findings describe patterns observed in the studies over the very brief, defined time intervals. The consistency of findings across these short-term evaluations is broadly classified as High, though the results apply only to the specific populations studied.

Evidence Landscape for Moderate to Severe Chronic Pain

For conditions characterized by fluctuating or episodic manifestations that may require management over a longer duration, the evidence base was evaluated in settings using exploratory RCTs, observational studies, and open-label cohorts. These studies generally explored areas where symptoms may vary in intensity, using outcomes reflecting daily functioning or activity level as key metrics. The evidence quality varies across studies for this context, with the strength of controlled data generally assessed as Moderate to Low when compared to the acute pain evidence base.

Gaps in Evidence and Areas of Uncertainty

Scientific review of the product’s research structure indicates several key limitations. Follow-up durations were limited in most controlled trials. Additionally, comparative evidence is lacking for certain contexts, particularly in chronic pain, where few studies directly compare the combination product against high-quality non-opioid pain relievers over extended periods. Furthermore, evidence quality varies across studies, and in some research areas, findings were mixed, reflecting the complexity of conditions where symptoms may vary in intensity. Evidence is still developing in the broader pain management field.

Key Studies & References Oxycodone and Acetaminophen Combination (MedlinePlus/NIH context)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Percocet 7.5/325 (FAQ)

Q: What is Percocet 7.5/325 used for?

The product label indicates that Percocet 7.5/325 is a combination medication for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The drug's label information indicates it is used for short-term pain relief.

Q: How should I store Percocet 7.5/325?

The product label generally advises storing the medication at room temperature, away from moisture and heat. Due to the opioid component, it is important to store it securely in a location inaccessible to children and pets.

Q: What should I do if I miss a dose?

If a dose is missed, the recommended approach is usually to take the missed dose only if it is not close to the time for the next scheduled dose. Never take two doses to make up for a missed one. It is important to follow the specific instructions provided by your healthcare professional regarding missed doses.

Q: Can I take other pain relievers with Percocet?

Taking other medications that contain acetaminophen (paracetamol) while taking Percocet 7.5/325 may increase the risk of liver damage, as Percocet already contains acetaminophen. You should speak with a healthcare professional before combining Percocet with any other pain relievers, especially over-the-counter products.

Q: Is Percocet habit-forming?

Percocet contains an opioid (oxycodone) and carries a risk of dependence, abuse, and misuse, which may lead to addiction. It is generally intended for short-term use and must be taken exactly as prescribed to mitigate these risks.

Advertisements

How should Percocet 7.5/325 be stored and disposed of?

Percocet (Oxycodone and Acetaminophen) tablets must be stored according to strict regulatory requirements to ensure security and product quality. Due to the high risk of fatal accidental ingestion, the medication must be stored securely, out of sight and out of reach of children and household visitors [Source: DailyMed].

Storage Condition Requirement
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F) [Source: FDA Labeling]
Container Keep the bottle tightly closed and protect from moisture [Source: FDA Labeling].

Expired or unused tablets must be disposed of promptly. The preferred method is using an authorized Drug Enforcement Administration (DEA)-registered take-back program. If no program is readily available, the FDA allows the product to be mixed with an unappealing substance (like cat litter or dirt), sealed in a plastic bag, and placed in the household trash [Source: DailyMed].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Percocet 7.5/325 found in:

A-Z Index: